案例 Products
产品名称

Bone & Osteoporosis

发布时间 2018-03-04
点击次数 142
  • 基本参数
  • 部件材质
  • 应用概述
  • 相关下载

     Bone & Osteoporosis

     

     Introduction


     Bone provides protection to visceral organs, storage of minerals, locomotive movement and are 

the locations of hematopoiesis. Structural integrity of bone can be affected by factors of aging, 

dietary imbalance, disuse, environmental contamination, infections, medicine, metabolic disorders, 

physical loading, radiation, smoking and trauma. Efficacy and safety data of the developing 

therapeutics to bone in animal models are required to predict the effects in human for excluding 

the toxicity of it.

     Bone fragility increases with age in both genders, and most notably after menopause in female. 

Anti-resorptive agents are well established, such as bisphosphonates, SERMs and likely anti-RANKL 

antibodies. Anabolic agents are actively being developed. Besides PTH analogues and stem cells, 

molecules from BMP family and Wnt signal pathways, such as Smads, ERK, Dkk-1, Runx2, 

and beta-catenin are targets for therapeutics. Safety and efficacy data of bone in animal

models (rodents and non-human primates) are required to predict the therapeutic effects in human.

     

     PharmaLegacy Models and Research Tools


     At PharmaLegacy, our scientists have cumulated more than two centuries of experiences in 

bone physiopathology, especially in bone safety, metabolic bone diseases, osteoarthritis and osteoporosis. 

Our familiarity with IND/NDA and SOP driven GLP quality assurance operations can aid your regulatory submission.

     

     

     In Vivo Models

     Mouse

                               *Antigen, chemical and collagen induced arthritis for systemic and local modalities.

                               *Calvaria periosteal injection for assessing bone formation or resorption capability.

Bone & Osteoporosis


     *Dietary alterations for body composition.

     *Estrogen-deficient bone loss for screening anti-resorption or anabolic agents.

     *Steroid-induced bone loss for seeking agents of osteopenia antagonist.

Rat

     *Bone safety for evaluating therapeutic effects on skeletal integrity, short or long term.Bone & Osteoporosis

    *Disuse bone loss for examining anti-resorptive and anabolic agents.

     *Dietary alterations for body composition.

     *Estrogen deficient bone loss for screening anti-resorptive and anabolic agents.

     *Renal osteodystrophy for seeking bone quality and quantity improvement agents.

     *Steroid-induced bone loss for identifying agents of osteopenia antagonist.

     *Testosterone deficient bone loss for screening anti-resorptive and anabolic agents.

     Non-Human Primate

     *Pharmacokinetic evaluation of dose range and short-term effects on biomarkers of bone.

     *Estrogen deficient bone loss for screening therapeutic effects on biomarkers of bone.

     *Bone safety for evaluating therapeutic effects on skeletal integrity, long term with biopsies.





     Ex Vivo Models

     *Biomechanics of bone properties.

     *Serum and urine biomarkers of bone remodeling.

     *Densitometry of pDEXA, micro-CT and pQCT on bone mineral.

     *Static and dynamic histomorphometry of bone cells and tissue, and quality of bone matrix.




Products / 相关产品
2018 - 03 - 05
Rheumatoid Arthritis        Introduction        Rheumatoid arthritis (RA) is a systemic inflammatory disorder characterized by chronic inflammation of...
2018 - 03 - 05
Osteoarthritis         Introduction         Osteoarthritis (OA), known as degenerative joint disease, involves both articular cartilage and subchondra...
2018 - 03 - 04
Bone Safety         Bone Structure         A.Align to biomechanical loading         Anatomical structure of bones depends mai...
Copyright ©2013 - 2018 
澎立生物医药技术(上海)有限公司
X
1

QQ设置

3

SKYPE 设置

4

阿里旺旺设置

5

电话号码管理

  • +86-21-6100-2270
6

二维码管理

等待加载动态数据...

等待加载动态数据...

回到顶部
展开